SASKATOON, Saskatchewan–(BUSINESS WIRE)–ZYUS Life Sciences Corporation (“ZYUS” or the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company leading scientific research and global development of innovative cannabinoid-based pharmaceutical drug products, today announced its 2023 Third Quarter Business results. During the third quarter of 2023, the Company completed an evaluation of the transactions relating to the Arrangement Agreement with Phoenix and the accounting treatment of tho
The informative cannabis social network. Join groups, make friends and be part of the cannabis community! Share your recipes, product & strain reviews, tutorials and more! Log in or register to continue
- Loading stock data...
- The Cannabist Company Highlights Product Innovation with Launch of Unique Fast-Acting and Longer-Lasting Layered Edibles
- Tenet to Participate in Barclays 26th Annual Global Healthcare Conference
- IGC Pharma Reports Third Quarter Fiscal 2024 Results
- Brown-Forman Announces Sale of Cooperage in Alabama
- American Weed Co. is First-Ever Cannabis Brand to Headline Sponsor Major U.S. Music Festival